Docetaxel and epirubicin compared with docetaxel and prednisone in advanced castrate-resistant prostate cancer: a randomised phase II study.

Br J Cancer · 2011 · PMC3049601 · PMID 21285986

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The D/EPI arm showed a trend towards a superior improvement in a number of quality of life dimensions compared with the D/P arm, particularly pain and physical function subscales, and global quality of life.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.